RajStockWatch

#WATCH | Mumbai, Maharashtra: On the stock market performance and investors' demand to re-evaluate the tax system, Union Finance Minister Nirmala Sitharaman says, "On this specific issue, and on any issue, we are always ready and willing to listen to the people. We will certainly take their (share market investors') inputs..." On the Rupee, she says, "As I have mentioned, we have a lot of input and suggestions, not only on the rupee but also concerning investments. We have gathered a vast amount of feedback; some of it has come in voluntarily from the public, while other inputs have been collected internally through various departments. We are currently reviewing every single one of these suggestions..."

📌 Viviana Power Tech Limited informed the exchange about its approval for the financial results for the period ended March 31, 2026. #SME #VIVIANA 📄🧾

📌 Enfuse Solutions Limited informed the exchange about its approval for the financial results for the period ended March 31, 2026. #SME #ENFUSE 📄🧾

📌 Novus Loyalty Ltd informed the exchange about its approval for the financial results for the period ended March 31, 2026. #SME #NOVUS 📄🧾

📌 Cosmic CRF Ltd informed the exchange about its approval for the financial results for the period ended March 31, 2026. #SME #COSMICCRF 📄🧾

📌 Shree Refrigerations Ltd informed the exchange about its approval for the financial results for the period ended March 31, 2026. #SME #SHREEREF 📄🧾

📌 Kabra Jewels Limited informed the exchange about its approval for the financial results for the period ended March 31, 2026. #SME #KKJEWELS 📄🧾

📌 Dhara Rail Projects Limited informed the exchange about its approval for the financial results for the period ended March 31, 2026. #SME #DHARARAIL 📄🧾

🧵 India's biggest-ever SME IPO opens this week. Q-Line Biotech (#QLine): set to raise ₹214 Cr. of fresh issue with marquee anchor investors (#abakkus #carnelian #HDFC #360One) & many more. Skip the hype and a deep dive into RHP raises serious concerns investors need to consider while evaluating the IPO for investment 🚩A company that sells 65% to its own group → guarantees ₹46 Cr of that group's debt → can't convert profit to cash → sits on 10 months of inventory → gets downgraded 4 notches by CRISIL → shares an office with an IT-raided entity it claims to have exited → belongs to a group named in a ₹500–700 Cr pathology scam → and books a ₹17 Cr loss it won't explain. 🚩 #1 — It sells 65% to its own group: POCT Services 283 distributors on paper. In reality, one group entity — POCT Services — absorbs more than 60%+ of all sales. % revenue share, year by year: ▪ FY23: 37.9% ▪ FY24: 51.7% ▪ FY25: 62.9% ▪ 9M FY26: 65.4% This isn't a distribution network. It's a related party. And the dependence deepens every single year — the opposite of what you want to see before an IPO. 🚩 #2 — It also backstops that group's debt It sells to the group. Does it also stand behind the group financially? Yes. Corporate guarantees in the contingent-liability note: ▪ POCT Science House: ₹10.6 Cr (Mar'25) → ₹15 Cr (Dec-25) ▪ POCT Services: ₹31.05 Cr (brand new in Dec-25) ▪ Total: ₹46 Cr — up from ZERO in FY23 & FY24 See the loop: Q-Line books revenue selling to POCT, and simultaneously guarantees POCT's borrowings. Revenue and risk circulate inside the same family. If POCT stumbles, Q-Line — and now its public shareholders — are on the hook 🚩 #3 — The profits don't become cash A healthy business converts profit into cash. This one doesn't. Net cash from operations: ▪ FY23: +₹25 Cr ▪ FY24: −₹24 Cr ❌ ▪ FY25: −₹1.3 Cr ❌ ▪ 9M FY26: −₹33 Cr ❌ Three straight years of negative operating cash flow — Reported profit on the P&L, real cash walking out the door. 🚩 #4 — Where the cash is trapped It's stuck in receivables and inventory that keep swelling. Debtor days: 66 (FY23) → 96 (FY25) → 160 (Dec-25) Inventory days: 180 (FY23) → 226 (FY25) → 305 (Dec-25) That's ~10 months of inventory sitting idle, and customers taking 5+ months to pay. Recall who the biggest customer is. And the company's own projections keep debtor days at 115 through FY28. They aren't promising a fix — they're normalising the bloat. 🚩 #5 — CRISIL has already downgraded the credit rating On April 9, 2026, CRISIL: ▪ Cut long-term: BBB+/Stable → B/Stable (four notches) ▪ Cut short-term: A2 → A4 ▪ Tagged it "Issuer Not Cooperating" — the company stopped sharing information. A four-notch downgrade, weeks before the IPO, and the firm went dark on its own rating agency. Yet it's comfortable asking the public for ₹214 Cr. 🚩 #6 — The "clean exit" that wasn't Now the governance gets uncomfortable. The Income Tax Dept ran search & seizure operations on POCT Science House Pvt Ltd (Sep 2–5, 2025); books and records were impounded. Q-Line says it divested its 49% stake on Mar 20, 2025 — a clean break. Except: ▪ POCT Science House still operated from the SAME office as Q-Line ▪ Its guarantee from Q-Line ROSE from ₹10.6 Cr (Mar'25) to ₹15 Cr (Dec'25) — AFTER the supposed exit If you've genuinely walked away, why the shared address — and why put MORE money on the line for them? 🚩 #7 — And the group has a documented history This is where it stops being about accounting. An NDTV investigation (Sep 6, 2025) into Madhya Pradesh's govt pathology-lab scandal names the winning consortium as "Science House Medicos and POCT Services." NDTV reported: ▪ 85 govt labs billed at premium NABL rates — NONE were NABL-accredited at contract start ▪ Scam estimated at ₹500–700 Cr, with ≥₹300 Cr in overbilling ▪ FDA-approved machines required, never used; single-bidder re-tender rule ignored ▪ Science House's promoter had served jail time for corruption; POCT blacklisted in multiple states ▪ The Economic Offences Wing had already filed a case "Science House" is a JV of Q-Line with its erstwhile associate POCT Science House. ndtv.com/india-news/ndt… ⚠️ #8 — The ₹17 Cr that simply vanished One number we could not reconcile. The restated P&L books an Extra-Ordinary Item of ₹16.97 Cr (~₹17 Cr) in FY25 — large enough to drag PAT down from ~₹34 Cr (FY24) to ~₹28 Cr (FY25). We searched the RHP for what this loss actually was but couldn't find the answer. 🔍 #9 — And note where it chose to list : SME and not Mainboard! A ₹214 Cr raise is the largest SME IPO in history. The minimum lot here is ~₹2.74 lakh — which prices out small retail and the questions they'd bring. A record-sized raise, riding the lighter-scrutiny lane, with a ticket size that keeps the smallest investors out. Not illegal. Summary : Are we reading too much or lining all the flags are telling one coherent story, not eight random ones! Do your own work. This is educational analysis, not investment advice. 🙏 #QLineBiotech #SMEIPO #IPO #IndianEquities #NSESME #StockAlertsIndia #stockmarkettrading

📌 Sacheerome Limited informed the exchange about its approval for the financial results for the period ended March 31, 2026. #SME #SACHEEROME 📄🧾

📌 Mahamaya Lifesciences Ltd informed the exchange about its approval for the financial results for the period ended March 31, 2026. #SME #MAHALIFE 📄🧾